How much is a tumor like a wound? Will tumor cells interact with the body's normal muscle stem cells, co-opting them for advantage to the tumor? Can IL-4 Receptor antibodies block this process? These are the questions in our NIH R01 grant application that was scored this week in the top 4% of grants for that review cycle (usually, the top 9% of grants are funded). We're very excited about this grant, and the probable 5 years of funding to pursue these question that we think will benefit patients with rhabdomyosarcoma in a tangible way. Kudos to Megan, who took strong work by Imran, Tohru and GH to the next level and made this project possible.